- ‘We’ve been looking for a novel approach’: Why Novartis CEO ended ADC holdout for $1.5B Myricx dealFor years, as Big Pharma poured billions into ADCs, Novartis CEO Vas Narasimhan notably stayed on the sidelines. Asked by Fierce during Novartis’ Q2 earnings call, Narasimhan explained why he is en…Fierce Biotech · 3d ago↗ source
- STAT+: Nabla’s new CEO on plan to gain market share in a competitive AI scribe environmentAmbient scribe developer Nabla said Brian Manning will be the Paris-based company's new CEO as it looks to grow in a highly competitive market.STAT · 3d ago↗ source
- STAT+: Novo Nordisk sues Eli Lilly over GLP-1 drug ads it calls ‘deceptive’Novo Nordisk sued Eli Lilly for allegedly running a “deceptive” ad campaign that uses “outdated clinical trials” to make its obesity and diabetes drugs appear more effective.